Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1TFT

NMR Structure of an Antagonists of the XIAP-Caspase-9 Interaction Complexed to the BIR3 domain of XIAP

Summary for 1TFT
Entry DOI10.2210/pdb1tft/pdb
Related1g3f 1tfq
DescriptorBaculoviral IAP repeat-containing protein 4, ZINC ION, 1-[3,3-DIMETHYL-2-(2-METHYLAMINO-PROPIONYLAMINO)-BUTYRYL]-4-PHENOXY-PYRROLIDINE-2-CARBOXYLIC ACID(1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-YL)-AMIDE (3 entities in total)
Functional Keywordscomplex, ligand-protein, apoptosis, bir, xiap
Biological sourceHomo sapiens (human)
Cellular locationCytoplasm: P98170
Total number of polymer chains1
Total formula weight14025.05
Authors
Primary citationOost, T.K.,Sun, C.,Armstrong, R.C.,Al-Assaad, A.S.,Betz, S.F.,Deckwerth, T.L.,Ding, H.,Elmore, S.W.,Meadows, R.P.,Olejniczak, E.T.,Oleksijew, A.K.,Oltersdorf, T.,Rosenberg, S.H.,Shoemaker, A.R.,Tomaselli, K.J.,Zou, H.,Fesik, S.W.
Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer.
J.Med.Chem., 47:4417-4426, 2004
Cited by
PubMed Abstract: Inhibitor of apoptosis (IAP) proteins are overexpressed in many cancers and have been implicated in tumor growth, pathogenesis, and resistance to chemo- or radiotherapy. On the basis of the NMR structure of a SMAC peptide complexed with the BIR3 domain of X-linked IAP (XIAP), a novel series of XIAP antagonists was discovered. The most potent compounds in this series bind to the baculovirus IAP repeat 3 (BIR3) domain of XIAP with single-digit nanomolar affinity and promote cell death in several human cancer cell lines. In a MDA-MB-231 breast cancer mouse xenograft model, these XIAP antagonists inhibited the growth of tumors. Close structural analogues that showed only weak binding to the XIAP-BIR3 domain were inactive in the cellular assays and showed only marginal in vivo activity. Our results are consistent with a mechanism in which ligands for the BIR3 domain of XIAP induce apoptosis by freeing up caspases. The present study validates the BIR3 domain of XIAP as a target and supports the use of small molecule XIAP antagonists as a potential therapy for cancers that overexpress XIAP.
PubMed: 15317454
DOI: 10.1021/jm040037k
PDB entries with the same primary citation
Experimental method
SOLUTION NMR
Structure validation

237992

数据于2025-06-25公开中

PDB statisticsPDBj update infoContact PDBjnumon